BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28322607)

  • 1. Can a nanoparticle that mimics Salmonella effectively combat tumor chemotherapy resistance?
    Mercado-Lubo R; McCormick BA
    Nanomedicine (Lond); 2017 Apr; 12(7):705-710. PubMed ID: 28322607
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine: the promise and challenges in cancer chemotherapy.
    Naguib YW; Cui Z
    Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034
    [No Abstract]   [Full Text] [Related]  

  • 8. Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance.
    Li S; Zhang W; Yin X; Xing S; Xie HQ; Cao Z; Zhao B
    Anticancer Agents Med Chem; 2015; 15(4):423-32. PubMed ID: 25929575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies in melanoma therapy: can nanoparticles overcome chemoresistance?
    Badea I
    Nanomedicine (Lond); 2017 Jul; 12(14):1623-1626. PubMed ID: 28635551
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.
    Bar-Zeev M; Assaraf YG; Livney YD
    Oncotarget; 2016 Apr; 7(17):23322-34. PubMed ID: 26989076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
    Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmable nanomedicine: synergistic and sequential drug delivery systems.
    Pacardo DB; Ligler FS; Gu Z
    Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Strategies in Cancer Nanomedicine.
    Tong R; Kohane DS
    Annu Rev Pharmacol Toxicol; 2016; 56():41-57. PubMed ID: 26514197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.
    Marchal S; El Hor A; Millard M; Gillon V; Bezdetnaya L
    Drugs; 2015 Sep; 75(14):1601-11. PubMed ID: 26323338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
    Cascorbi I; Haenisch S
    Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
    Modok S; Mellor HR; Callaghan R
    Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor.
    Yin Q; Shen J; Zhang Z; Yu H; Li Y
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1699-715. PubMed ID: 23611952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.